Health TrialsbyHealthPanel

Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière

ConditionsIschemic StrokeHemorrhagic Stroke
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-100
SponsorAssistance Publique - Hôpitaux de Paris

About this trial

Neurovascular diseases can cause ischaemic or haemorrhagic strokes. While the most common, such as atherosclerosis are widely studied, others are less well known, such as arterial dissections or cerebral angiopathies. What's more, most studies are limited to a few years' follow-up and the longer-term evolution of patients is less well assessed. Patient follow-up data available in routine practice and specific enrollment through the headache emergencies of the Lariboisière neurovascular intensive care unit (USINV) could provide a particularly rich resource.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adult patients ≥18 years

Patients admitted to the Neurovascular Intensive Care Unit with acute cerebrovascular disease OR Patients managed for acute cerebrovascular pathology with or without stroke by the Lariboisière neurology team.

No opposition from the patient to the research and for patients under guardianship or guardianship or lack of capacity to object (severe impairment of cognitive functions, dementia, etc.), no opposition from the legal representative.

Disqualifiers

Patient refusing to take part in the study or refusal by the legal representative in the case of patients under guardianship or curatorship

Patient suffering from a rare neurovascular disease and being followed at the "Centre de référence des maladies vasculaires rares du cerveau et de l'oeil" (CERVCO)

Trial population

Adult patients treated for acute cerebrovascular disease

Trial design

Design model

Cohort

Time perspective

Cross-sectional

Treatments tested in this trial

  • follow-up

    Other intervention

    Long term follow-up

Treatment groups

5,000 Participants
are divided into 1 treatment group
Group A: Patients treated for acute cerebrovascular pathology cerebrovascular disease1 intervention

Trial outcomes

Primary outcomes

1

Incidence of a vascular event

Vascular event is defined as : myocardial infarction, ischaemic or haemorrhagic stroke, recurrence of cerebrovascular disease, systemic embolism, congestive heart disease, vascular or non-vascular death during patient follow-up.

Time frame
Up to 5 years

Secondary outcomes

1

Incidence of a vascular event

Vascular event is defined as : myocardial infarction, ischaemic or haemorrhagic stroke, recurrence of cerebrovascular disease, systemic embolism, congestive heart disease, vascular or non-vascular death during patient follow-up.

Time frame
Up to 10 years
2

Modified Rankin score

The modified Rankin score is a 6 point disability scale varying between 0 to 5. The higher the score, the greater the disability.

Time frame
At 3 months
3

Modified Rankin score

The modified Rankin score is a 6 point disability scale varying between 0 to 5. The higher the score, the greater the disability.

Time frame
At 1 year
4

Modified Rankin score

The modified Rankin score is a 6 point disability scale varying between 0 to 5. The higher the score, the greater the disability.

Time frame
At 2 years

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Assistance Publique - Hôpitaux de Paris

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: